NAGE
Niagen Bioscience Inc NASDAQ Listed Jun 24, 2015$4.19
Mkt Cap $335.5M
52w Low $4.04
1.4% of range
52w High $14.69
50d MA $4.76
200d MA $6.89
P/E (TTM)
22.1x
EV/EBITDA
28.0x
P/B
5.0x
Debt/Equity
0.0x
ROE
22.7%
P/FCF
38.3x
RSI (14)
—
ATR (14)
—
Beta
2.23
50d MA
$4.76
200d MA
$6.89
Avg Volume
1.2M
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
10900 Wilshire Blvd, Suite 600 · Los Angeles, CA 90024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.06 | 0.07 | +16.7% | 4.97 | -12.3% | -15.7% | — | — | — | — | — |
| Mar 4, 2026 | AMC | 0.02 | 0.03 | +50.0% | 4.94 | +15.2% | +3.2% | -0.8% | +1.0% | +2.2% | -6.3% | — |
| Nov 4, 2025 | AMC | 0.01 | 0.05 | +233.3% | 6.95 | +8.6% | -1.0% | -4.1% | +3.6% | +3.8% | +0.8% | — |
| Aug 6, 2025 | AMC | 0.02 | 0.04 | +100.0% | 9.40 | +19.1% | +2.2% | +1.2% | +0.9% | +4.5% | -1.4% | — |
| May 7, 2025 | AMC | 0.02 | 0.04 | +100.0% | 8.45 | +5.2% | +9.3% | -3.1% | +4.9% | +3.6% | +3.8% | — |
| Mar 4, 2025 | AMC | 0.02 | 0.03 | +50.0% | 5.60 | +19.8% | +52.7% | -10.1% | +0.1% | +2.3% | +0.3% | — |
| Oct 31, 2024 | AMC | 0.01 | 0.02 | +100.0% | 3.49 | +18.1% | +67.9% | -2.0% | +6.4% | +14.4% | -3.1% | — |
| Jun 30, 2024 | AMC | -0.02 | -0.00 | +99.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | -0.02 | -0.01 | +67.5% | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | -0.02 | 0.00 | +106.7% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.03 | -0.01 | +57.3% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.04 | -0.03 | +27.0% | 1.57 | -1.3% | -1.3% | +3.2% | -2.5% | +1.3% | +3.8% | — |
| Mar 31, 2023 | AMC | — | -0.03 | — | 1.53 | +1.3% | -1.3% | -4.0% | +2.1% | -2.0% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.28 | $4.36 | +1.9% | +3.0% | +2.5% | -3.1% | +2.1% | +0.0% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.94 | $5.69 | +15.2% | +3.2% | -0.8% | +1.0% | +2.2% | -6.3% |
| Nov 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.95 | $7.55 | +8.6% | -1.0% | -4.1% | +3.6% | +3.8% | +0.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.73 | $9.94 | +2.2% | +0.9% | +4.5% | -1.4% | -4.1% | +3.2% |
| Jun 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.43 | $13.43 | +0.0% | +0.7% | +4.1% | +0.5% | -3.6% | +3.7% |
| Jun 6 | Roth Capital | Maintains | Buy → Buy | — | $11.51 | $11.94 | +3.7% | +12.5% | +3.7% | +0.7% | +4.1% | +0.5% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.62 | $5.96 | +6.0% | -3.6% | +11.4% | -6.1% | +4.6% | +3.5% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $6.60 | -2.5% | +1.9% | -0.4% | +3.1% | -6.4% | -9.2% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.84 | $7.83 | -0.1% | +1.3% | -0.9% | -1.7% | -1.3% | +1.4% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.80 | +1.3% | +2.3% | +0.3% | -0.9% | -1.4% | +1.6% |
| Mar 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.60 | $6.71 | +19.8% | +52.7% | -10.1% | +0.1% | +2.3% | +0.3% |
| Nov 6 | Roth MKM | Maintains | Buy → Buy | — | $6.11 | $6.44 | +5.4% | +14.4% | -3.1% | -4.0% | +7.8% | +3.4% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.86 | $5.72 | -2.4% | -2.0% | +6.4% | +14.4% | -3.1% | -4.0% |
No insider trades available.
8-K · 2.02
!! High
Niagen Bioscience Inc -- 8-K 2.02: Earnings Results
Niagen Bioscience released earnings results, with detailed financial performance available in the attached press release, though specific metrics require review of the full disclosure.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ZEOX gains credibility and marketing exposure by partnering with A4M at a major longevity conference, positioning itself alongside established public competitors to attract institutional investors and accelerate clinical advancement.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
NAGE's $10 billion share buyback authorization signals management confidence and will reduce share count, boosting earnings per share and potentially supporting stock price during market volatility.
Mar 19
8-K · 7.01
! Medium
Niagen Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
Niagen Bioscience released a corporate presentation on March 4, 2026, providing updated company information to investors and the public through regulatory disclosure channels.
Mar 4
8-K · 8.01
!! High
Niagen Bioscience, Inc. -- 8-K 8.01: Material Event / Announcement
Niagen Bioscience agreed to sell its analytical reference standards and services business to VHG Labs, a LGC Group subsidiary, in an all-cash transaction that will streamline operations.
Feb 26
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.
Feb 4
Data updated apr 26, 2026 2:09pm
· Source: massive.com